Agilent Technologies Inc (A) Stock Price Today
Aura AI Summary
Key Stats
- $43.30BMarket Cap
- -Volume
- HealthSector
- $158.9352W High
- $110.2452W Low
- -Typical Hold Time
- $45.49BEnterprise Value
- 0.66%Div Yield
- -Trading Activity
Track Agilent Technologies Inc (A) stock price today on Pluang, updated in real time with live charts and market data. Over the past 52 weeks, Agilent Technologies Inc has traded between a low of $110.24 and a high of $158.93, highlighting its annual price range. Buy and sell Agilent Technologies Inc shares on Pluang with fractional shares and real-time market data — safe and OJK-regulated.
About Agilent Technologies Inc
Originally spun out of Hewlett-Packard in 1999, Agilent has evolved into a leading life sciences and diagnostics firm. Today, Agilent's measurement technologies serve a broad base of customers with its three operating segments: life science and applied tools (45% of fiscal 2021 sales), cross lab (35% of sales consisting of consumables and services related to its life science and applied tools), and diagnostics and genomics (20%). Over half of its sales are generated from the biopharmaceutical, chemical, and energy end markets, but it also supports clinical lab, environmental, forensics, food, academic, and government-related organizations. The company is geographically diverse, with operations in the U.S. (34%) and China (20%) representing the largest country concentrations.
Most Recent News
Nutex Health hit by ransomware; patient and employee data stolen and threatened for release
Nutex Health, a micro-hospital operator, suffered a ransomware attack by The Gentlemen group, which accessed and stole confidential patient, employee, and business data. The attackers threatened to publish the stolen information, increasing risks of ...
Oil prices rise over 2% amid escalating US-Iran tensions and attacks in the Middle East
Oil prices surged as tensions in the Middle East escalated following recent US strikes on Iran and retaliatory attacks by Iran on US allies Kuwait, Jordan, and Bahrain. Brent crude futures rose over 2% to $96.59 a barrel, while US West Texas Intermed...
Alumis stock plunges 57% after lupus drug trial fails, but psoriasis drug progress continues.
Alumis' stock dropped 56.58% after its Phase II lupus drug trial failed to meet main goals, causing a significant market reaction. However, positive results in a subgroup of lupus patients with a high interferon gene signature offer a potential path ...
People also bought
Frequently Asked Questions
All investments involve risks and the possibility of a loss in investment value. Past performance is not indicative of future results. Historical performance, expected returns, and probability projections are provided for informational and illustrative purposes only.